How Do You Test for Mold Toxicity: A Plain-Language Guide
How you test for mold toxicity depends entirely on what “mold toxicity” means in your specific situation — and the term itself is contested in clinical medicine. This guide walks through the testing options people typically consider, what each one measures, where mainstream medical organizations stand on their clinical validity, and how the home-inspection side fits in. The site’s expertise is residential inspection, not medical diagnostics; the framing here is what homeowners should know before talking to a doctor, never a substitute for that conversation. Our editorial approach to health-adjacent content is documented on our methodology page. The summaries below reflect CDC, NIEHS, EPA, and ATSDR guidance current as of 2026.
Is this mold, asbestos, or water damage? Get a free instant screen
Upload a clear photo of the suspect area. You'll get an instant AI screening opinion and what to do next. This is screening guidance, not a professional determination.
Screening guidance only. AI can be wrong. Confirm asbestos, mold type, or lead with lab testing or a licensed professional before acting.
What does “mold toxicity” actually mean?
“Mold toxicity” is a consumer-market term that doesn’t quite match how mainstream clinical medicine categorizes mold-related illness. The medical literature recognizes several distinct conditions: IgE-mediated allergy, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, and invasive infections in immunocompromised patients. A unified “mold toxicity” diagnosis covering chronic fatigue, brain fog, joint pain, and a broad range of systemic symptoms is not currently a consensus diagnosis among mainstream medical organizations.
This doesn’t mean people aren’t genuinely sick or that mold exposure can’t cause real harm. It means the diagnostic landscape marketed under the “mold toxicity” label includes tests with very different evidence bases, and consumers deserve to understand what each one actually measures before paying out of pocket.
Urine mycotoxin testing
Urine mycotoxin tests are the most prominently marketed option in the mold-toxicity testing space. They look for breakdown products of mold-produced toxins — ochratoxin A, aflatoxin, trichothecenes, gliotoxin, zearalenone — in a urine sample. Several private labs offer these tests directly to consumers or through naturopathic and functional medicine practitioners at $300 to $700 per panel.
The interpretation challenges are well documented. Mycotoxins enter the body through dietary sources (grains, coffee, dried fruit, peanuts, certain spices) as well as inhalation, so a positive urine result doesn’t isolate home mold as the cause. Peer-reviewed clinical validation literature is limited. Public-health agencies including NIEHS and CDC have not endorsed urine mycotoxin testing as a validated diagnostic tool for mold-related illness. A physician may still order one as part of a broader workup; the result should be interpreted in clinical context.
Blood tests: IgE and IgG
Blood-based mold testing falls into two distinct categories with different evidence bases. IgE testing measures specific IgE antibodies against mold antigens and detects allergic sensitization. It is the most well-established mold-related test in mainstream allergy practice, ordered by board-certified allergists for patients with allergy-pattern symptoms.
IgG antibody panels measure long-term antibody response to mold antigens. Mainstream public-health bodies including NIEHS and CDC have not endorsed IgG panels as a validated diagnostic for generalized mold-related illness. They have a narrow validated role in specific conditions like hypersensitivity pneumonitis when ordered and interpreted by a specialist. A consumer-ordered IgG panel showing reactivity to common environmental molds is generally not a basis for self-diagnosis.
Auxiliary and investigational tests
Several other tests appear in the mold-toxicity testing conversation. Visual contrast sensitivity (VCS) tests assess the patient’s ability to distinguish shades of gray; some practitioners use them as a screening tool. MARCoNS nasal swabs look for multiple antibiotic-resistant coagulase-negative staphylococci sometimes associated with chronic inflammatory response syndromes.
Various inflammation biomarker panels — measuring complement proteins, MMP-9, leptin, TGF-beta, and others — are marketed in this space. None of these is universally accepted as a stand-alone diagnostic for mold toxicity. A physician evaluating a specific clinical picture may incorporate one or more into a broader workup. A consumer ordering them without medical interpretation is unlikely to get actionable information.
What mainstream medical organizations say
The CDC’s mold guidance acknowledges that exposure to indoor mold can cause allergic reactions, asthma symptoms, and irritant effects, and that immunocompromised individuals face infection risk. It does not endorse a specific consumer “mold toxicity test.” The EPA’s stance is similar — focused on environmental remediation rather than medical testing.
Published guidance from NIEHS and CDC does not endorse urine mycotoxin testing or IgG mold panels as validated diagnostic tools for mold-related illness. ATSDR’s clinical guidance emphasizes individualized assessment by a physician familiar with the patient’s history. None of these positions deny that people get sick from mold exposure — they decline to endorse specific consumer-marketed tests as reliable diagnostic shortcuts.
What homeowners can do on the environmental side
The environmental side of the problem is where homeowners have direct leverage. A professional mold inspection can document visible growth, identify moisture sources, take laboratory air or surface samples when warranted, and produce a written report. The inspection answers a building question — is there a mold problem here, where is the moisture coming from — not a medical one.
This separation matters in both directions. A negative human test does not prove the home is mold-free. A positive home test does not prove the occupants’ symptoms are mold-related. Each side of the problem requires its own kind of expertise. The credible path forward typically combines both: the physician handles the body, the inspector handles the building.
Preparing for a medical visit
If you suspect mold exposure is contributing to symptoms, the most useful preparation for a medical appointment is not a self-ordered mycotoxin test. It is a clear timeline and environmental documentation. When did symptoms start? Who in the household is affected? What changed in the home around that time — a flood, leak, basement seepage, new HVAC work, recent renovations? Do symptoms improve when the affected person spends extended time away from the home and recur on return?
Photographs of any visible growth, moisture meter readings if available, and any existing inspection report give the physician environmental context. A board-certified allergist or pulmonologist will know which targeted tests are appropriate. Our overview of mold toxicity testing covers the testing-decision side in more depth.
Where consumer marketing exceeds the evidence
Direct-to-consumer mold testing expanded rapidly during the 2010s and 2020s. Several forces drove the growth: legitimate patient frustration with chronic unexplained symptoms, the rise of functional and integrative medicine, social media communities sharing experiences, and aggressive lab marketing. The underlying environmental concern — chronic indoor moisture and mold exposure is a real health issue — is well founded.
The diagnostic certainty implied by consumer-marketed panels often exceeds what the underlying clinical evidence supports. A urine mycotoxin test detecting ochratoxin metabolites is doing what it’s designed to do; whether that detection means the patient’s symptoms are mold-caused is a much harder question that the test itself doesn’t answer. Homeowners can navigate this landscape by working with physicians for the medical side and qualified inspectors for the home side.
When to escalate medical concern
Several scenarios warrant prompt medical evaluation regardless of how the testing question gets resolved. Persistent respiratory symptoms — wheezing, shortness of breath, chronic cough — justify primary care evaluation and possible pulmonology referral. Immunocompromised household members who develop respiratory symptoms in a home with visible mold should see infectious disease specialists; aspergillus and other fungal infections are known risks in these populations.
Severe allergy-pattern symptoms that don’t respond to standard antihistamines justify an allergist visit. Symptoms that consistently improve when an affected person leaves the home for several days and recur on return are a clinical pattern worth flagging to a physician — that pattern is consistent with environmental triggering, regardless of the underlying mechanism.
The home-side action plan
Whatever the medical workup shows, the home side is straightforward in principle: locate the moisture, fix it, remediate affected materials, verify the work. A qualified inspector — ideally not affiliated with a remediation contractor — can scope the problem and produce a written report. Front Range homeowners face recurring patterns (basement seepage from snowmelt, ice-dam leaks, condensation on poorly insulated walls) that experienced local inspectors recognize quickly.
The two sides of the problem complement each other. The physician handles the body; the inspector handles the building. A homeowner navigating this situation usually benefits from running both tracks in parallel, with each providing context for the other.
How sampling decisions tie back to medical questions
When a physician is involved in the workup, sampling decisions on the home side become more focused. A doctor asking whether environmental mold could be contributing to a specific clinical picture benefits from documented air-sampling data, species composition, and moisture mapping — not just a narrative description of the home. The inspection becomes part of the clinical record rather than a stand-alone document.
This is one scenario where ERMI or HERTSMI dust testing can earn its cost. The EPA does not recommend these DNA-based dust assays for routine residential use, but a physician treating a patient for suspected mold-related illness may specifically request this kind of environmental data. When that’s the case, the test is being ordered for a defined clinical purpose, not as a stand-alone consumer purchase.
Practical next steps for homeowners
If you’re trying to decide where to start, the most useful sequence is usually clinical first, environmental second. Talk to a physician about the symptom pattern. Get appropriate referrals to allergy, pulmonology, or infectious disease specialists if warranted. Then commission a home inspection if the clinical picture suggests environmental contribution, the home has visible moisture concerns, or a doctor specifically requests environmental documentation.
This sequence tends to produce more actionable information than the reverse. A home inspection in isolation answers the building question — but without a clinical picture, it may not connect to anything the patient can act on medically. A medical workup that incorporates environmental findings produces a more complete picture for the physician’s decision-making.
References
- CDC mold and health overview — Centers for Disease Control and Prevention
- NIEHS overview of mold and human health — National Institute of Environmental Health Sciences
- ATSDR clinical guidance on mold — Agency for Toxic Substances and Disease Registry
- EPA mold and health guidance — U.S. Environmental Protection Agency
Front Range homeowners addressing the environmental side of a possible mold problem can reach out through our contact page for a referral to a vetted independent inspector.